About cyclerion therapeutics inc - CYCN
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
CYCN At a Glance
Cyclerion Therapeutics, Inc.
245 First Street
Cambridge, Massachusetts 02142
| Phone | 1-857-327-8778 | Revenue | 2.07M | |
| Industry | Pharmaceuticals: Major | Net Income | -3,528,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3.7% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1 | |
| View SEC Filings |
CYCN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.948 |
| Price to Book Ratio | 0.534 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.161 |
| Enterprise Value to Sales | 0.386 |
| Total Debt to Enterprise Value | N/A |
CYCN Efficiency
| Revenue/Employee | 2,074,000.00 |
| Income Per Employee | -3,528,000.00 |
| Receivables Turnover | 2.074 |
| Total Asset Turnover | 0.212 |
CYCN Liquidity
| Current Ratio | 5.15 |
| Quick Ratio | 5.15 |
| Cash Ratio | 3.60 |
CYCN Profitability
| Gross Margin | N/A |
| Operating Margin | -239.778 |
| Pretax Margin | -170.106 |
| Net Margin | -170.106 |
| Return on Assets | -36.074 |
| Return on Equity | -39.342 |
| Return on Total Capital | -38.833 |
| Return on Invested Capital | -39.342 |
CYCN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |